Aequus Pharmaceuticals Inc.

AQS

CA0076361033

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 16:39:12 12/07/2024 BST			5-day change	1st Jan Change
0.03 ^CAD	-14.29%		-14.29%	+20.00%

07-03	Aequus Pharmaceuticals Inc. Signs Exclusive Distribution Agreement with Advanced Ophthalmic Innovations for the Paul® Glaucoma Drainage Device in Canada	CI
05-10	Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Aequus Pharmaceuticals Inc.(TSXV:AQS) added to S&P/TSX Venture Composite Index

January 22, 2018 at 05:00 am

Latest news about Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. Signs Exclusive Distribution Agreement with Advanced Ophthalmic Innovations for the Paul® Glaucoma Drainage Device in Canada	07-03	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23	CI
Aequus Says Zimed PF Now Available in Canada	24/08/23	MT
Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada	24/08/23	CI
Aequus Pharmaceuticals Announces Zimed PF Website Launch	22/08/23	MT
Aequus Pharmaceuticals Pauses Sales Of Evolve Intensive Eyedrops, Gel in Canada	18/08/23	MT
Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada	18/08/23	CI
Aequus Pharmaceuticals Announcds Financing to Support Launch of Zimed Preservative Free	07/07/23	MT
Aequus Pharmaceuticals Inc. Increases Its Debt by $400,000 to Support the Launch of Zimed Pf	05/07/23	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23	CI
Aequus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	30/04/23	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/04/23	CI
Aequus Pharmaceuticals Inc. Announces the Resignation of Stuart Fowler from the Board of Directors	05/04/23	CI
Aequus Announces Health Canada Notice of Compliance for Zimed® Preservative Free (Bimatoprost 0.03%)	20/12/22	CI
Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed PF	29/11/22	MT
Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free)	29/11/22	CI
Aequus Pharmaceuticals Inc. Agrees to End Its Promotional Service Agreement with Sandoz Canada Inc	29/11/22	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	28/11/22	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	30/08/22	CI
Aequus Pharmaceuticals Chairman and CEO Doug Janzen Increases Ownership Interest	25/07/22	MT
Aequus Signs Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products	07/07/22	MT
Aequus Pharmaceuticals Inc. Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products	06/07/22	CI

Chart Aequus Pharmaceuticals Inc.

Duration

Period

More charts

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.

Sector

Pharmaceuticals

Calendar

29/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AEQUUS PHARMACEUTICALS INC.	+20.00%	2.91M
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+31.64%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+15.51%	247B
NOVARTIS AG	+16.72%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B